. 2013 Dec 1;6(1):16–27.

Table 4.

Multivariable linear regression analyses of serum MPO levels (ng/mL)

Exposures of interest	Adjusted Mean (95% CI) or N	Adjusted relative change in MPO between groups (95% CI)	p-value
Psoriasis and control patients (N=153)
Presence of psoriasis
^*Model 1	Control: 1,130.4 (880.9, 1,450.5)	2.50 (1.84, 3.41)	<0.001
^*Model 1	Psoriasis: 2,829.1 (2,359.8, 3,391.8)	2.50 (1.84, 3.41)	<0.001
Model 2	Control: 1,146.5 (856.4, 1,534.7)	2.50 (1.84, 3.40)	<0.001
Model 2	Psoriasis: 2,866.7 (2,277.5, 3,608.3)	2.50 (1.84, 3.40)	<0.001
Model 3	Control: 1,133.9 (845.7, 1,520.4)	2.45 (1.79, 3.36)	<0.001
Model 3	Psoriasis: 2,779.4 (2,167.1, 3,564.8)	2.45 (1.79, 3.36)	<0.001
Model 4	Control: 1,076.7 (800.0, 1,449.1)	2.34 (1.71, 3.21)	<0.001
Model 4	Psoriasis: 2,519.9 (1,918.9, 3,309.3)	2.34 (1.71, 3.21)	<0.001
Model 5	Control: 1,090.3 (810.6, 1,466.6)	2.24 (1.62, 3.09)	<0.001
Model 5	Psoriasis: 2,440.9 (1,851.4, 3,218.3)	2.24 (1.62, 3.09)	<0.001
Model 6	Control: 1,095.0 (816.5, 1,468.4)	2.22 (1.61, 3.06)	<0.001
Model 6	Psoriasis: 2,432.1 (1,849.8, 3,197.8)	2.22 (1.61, 3.06)	<0.001

Model 1: MPO = exposure + age.

Model 2: Model 1 + gender. Model 3: Model 2 + waist-to-hip ratio. Model 4: Model 3 + current smoker. Model 5: Model 4 + systolic blood pressure. Model 6: Model 5 + HDL. CI: confidence interval; HDL: high density lipoprotein; MPO: myeloperoxidase; N: count.